论文部分内容阅读
该文报告选择１１６例慢乙肝分为３组，单磷酸阿糖腺苷联合胸腺肽治疗组（Ⅰ组）４６例，抗乙肝免疫核糖核酸治疗组（Ⅱ组）３６例，对照组（Ⅲ组）３４例。Ⅰ、Ⅱ、Ⅲ组ＨＢｅＡｇ阴转率分别为６３．９％，３１．３％和１６．７％；ＨＢＶＤＮＡ阴转率分别为５６．８％，１９．０％和１４．３％；抗ＨＢｃＩｇＭ阴转率分别为５６．０％，３３．３％和２５．９％。显示单磷酸阿糖腺苷联合胸腺肽治疗对乙肝病毒复制有较好的抑制作用，优于Ⅱ、Ⅲ组（Ｐ＜０．０１）。对２例乙、丙型肝炎病毒双重感染，治疗后ＨＢｅＡｇ与ＨＢＶＤＮＡ阴转，丙肝抗ＨＣＶ与ＨＣＶＲＮＡ也同时阴转，可能与胸腺肽作用有关。
In the report, 116 chronic hepatitis B patients were divided into 3 groups: 46 patients in group Ⅰ (group Ⅰ) and 36 patients in group Ⅱ (group Ⅱ) 34 cases. The negative conversion rates of HBeAg in group Ⅰ, Ⅱ and Ⅲ were 63.9%, 31.3% and 16.7% respectively; the negative conversion rates of HBVDNA were 56.8%, 19.0% and 14.3% respectively; the anti HBcIgM Negative conversion rates were 56.0%, 33.3% and 25.9% respectively. The results showed that combination of adenosine monophosphate and thymosin had a better inhibitory effect on hepatitis B virus replication than that of group Ⅱ and Ⅲ (P <0.01). Two cases of hepatitis B and C virus double infection, after treatment, HBeAg and HBVDNA overcast, anti HCV and HCV RNA HCV also negative conversion, may be related to the role of thymosin.